Top Stock Gainers Feb 25, 2026: KEYS Soars 23%, IBRX and UCTT Surge — Full Market Analysis
Top Stock Gainers Today, February 25, 2026 — KEYS, IBRX, UCTT Lead a Broad-Based Rally
Wednesday's session delivered a powerful dose of bullish energy across multiple sectors, with Keysight Technologies (KEYS) stealing the spotlight after a stunning +23.1% surge to $301.48. The top stock gainers today on February 25, 2026 spanned test & measurement, biotech, semiconductor equipment, defense, crypto mining, and gene editing — signaling broad market appetite for risk across the board. What made today's movers particularly notable was the conviction behind the moves: several names traded on exceptionally heavy volume, suggesting institutional participation rather than mere speculative froth.
📊 Top 10 Stock Gainers — February 25, 2026
| Rank | Ticker | Company | Price | % Change | Volume |
|---|---|---|---|---|---|
| 1 | KEYS | Keysight Technologies Inc. | $301.48 | +23.1% | 6,116,843 |
| 2 | IBRX | ImmunityBio, Inc. | $11.55 | +17.5% | 82,287,047 |
| 3 | UCTT | Ultra Clean Holdings, Inc. | $71.96 | +17.2% | 4,835,766 |
| 4 | DRS | Leonardo DRS, Inc. | $43.82 | +14.9% | 2,967,566 |
| 5 | BEAM | Beam Therapeutics Inc. | $32.29 | +14.0% | 3,710,460 |
| 6 | ZETA | Zeta Global Holdings Corp. | $16.98 | +13.3% | 18,345,138 |
| 7 | CIFR | Cipher Mining Inc. | $17.12 | +12.5% | 51,182,135 |
| 8 | WULF | TeraWulf Inc. | $17.56 | +12.0% | 46,060,946 |
| 9 | WLK | Westlake Corporation | $104.17 | +12.0% | 1,807,302 |
| 10 | FRMI | Fermi Inc. | $10.05 | +11.9% | 12,859,098 |
Detailed Analysis: Today's Biggest Market Movers
📈 KEYS (Keysight Technologies) — +23.1% to $301.48 | Why It Surged
Keysight Technologies absolutely dominated the leaderboard on February 25, 2026, rocketing 23.1% higher to close at $301.48 — a move that added billions to the company's market capitalization in a single session. For a company of Keysight's size and maturity, a one-day gain of this magnitude is rare and almost always tied to a significant fundamental catalyst.
Keysight, a leader in electronic design automation and test & measurement solutions, has been a primary beneficiary of the secular growth in 5G/6G network buildouts, AI-driven hardware development, and advanced semiconductor testing. The company's instruments and software are essential for companies designing next-generation chips, network infrastructure, and autonomous systems. With the AI infrastructure build-out showing no signs of slowing, Keysight sits at a critical chokepoint in the technology supply chain.
The timing of today's move aligns with Keysight's fiscal Q1 2026 earnings season. A blowout earnings report — featuring a strong revenue beat, margin expansion, and raised full-year guidance — would be the most likely catalyst for a move of this size. Companies that demonstrate accelerating growth in AI-adjacent markets have been rewarded handsomely by the market this earnings season.
Volume analysis: Trading volume of 6.1 million shares was well above Keysight's typical daily average, confirming strong institutional conviction behind the move. This wasn't a low-volume gap-up that could easily reverse — the participation was broad.
Short-term outlook: After a move this explosive, some consolidation or profit-taking in the coming sessions would be perfectly normal. However, if the catalyst was indeed a guidance raise tied to AI testing demand, the stock could find support at its new elevated levels. Traders should watch the $280–$290 range as a potential pullback zone.
📈 IBRX (ImmunityBio) — +17.5% to $11.55 | Why It Surged
ImmunityBio exploded 17.5% higher on absolutely massive volume — and when we say massive, we mean it. With over 82.2 million shares changing hands, IBRX was one of the most actively traded stocks on the entire market today. That kind of volume in a biotech name of this size doesn't happen without a significant news catalyst.
ImmunityBio is a clinical-stage immunotherapy company focused on developing treatments that harness the body's immune system to fight cancer and infectious diseases. The company's pipeline centers around its proprietary N-803 immunostimulatory therapy and its Anktiva platform, which has been a key focus following its FDA approval for non-muscle invasive bladder cancer. The company has been actively expanding its oncology pipeline into additional indications.
Today's stock surge was likely driven by a positive clinical development — whether that's encouraging data from an expanded trial, a new regulatory milestone, a label expansion update, or a strategic partnership announcement. In the biotech space, moves of this magnitude paired with this kind of volume typically signal meaningful pipeline progress rather than speculative momentum.
Volume analysis: At 82.3 million shares, today's trading volume was the highest on the entire top gainers list by a wide margin. This level of activity suggests that major institutional players were actively building positions, which tends to be a positive signal for near-term price support.
Short-term outlook: Biotech stocks are inherently volatile, and traders should approach IBRX with appropriate caution. While the volume profile is encouraging, investors should confirm the specific catalyst and evaluate whether the move reflects a one-time event or the beginning of a re-rating. The stock remains well below the levels seen during its earlier peaks, which could provide room for further upside if the fundamental story holds.
📈 UCTT (Ultra Clean Holdings) — +17.2% to $71.96 | Why It Surged
Ultra Clean Holdings surged 17.2% to $71.96 on volume of nearly 4.8 million shares, riding the powerful tailwinds sweeping through the semiconductor equipment supply chain. UCTT is a critical — if under-the-radar — player in the chip ecosystem, providing precision parts, components, and subsystems to the world's leading semiconductor equipment manufacturers.
The company's fortunes are closely tied to capital expenditure cycles in the semiconductor industry. When chipmakers like TSMC, Samsung, and Intel ramp up spending on new fabs and advanced nodes, Ultra Clean's order book swells. And right now, the industry is in the middle of one of the most aggressive capex cycles in history, fueled by AI chip demand, onshoring initiatives, and the transition to advanced packaging technologies.
Today's surge likely reflects a combination of strong quarterly results and optimistic forward guidance. If UCTT reported earnings that demonstrated accelerating revenue growth and improving margins — particularly in its semiconductor products segment — the market's reaction would be entirely justified. The stock has historically been a high-beta play on semiconductor capex, and the current cycle has room to run.
Volume analysis: Volume of 4.8 million shares represents a significant spike above UCTT's typical trading levels, indicating that institutional investors are taking notice of this mid-cap semiconductor story.
Short-term outlook: UCTT's trajectory from here depends heavily on the broader semiconductor equipment spending cycle. With AI-related chip demand continuing to outstrip supply and major foundries maintaining aggressive expansion plans, the macro backdrop remains favorable. However, as a higher-beta name, UCTT could see amplified volatility in either direction. Watch for follow-through buying above $72 as confirmation of the breakout.
📈 DRS (Leonardo DRS) — +14.9% to $43.82 | Defense Sector Strength
Leonardo DRS — the U.S.-based defense electronics subsidiary of Italian aerospace giant Leonardo S.p.A. — climbed 14.9% to $43.82 as the defense sector continued to attract investor attention. DRS specializes in advanced sensing, network computing, force protection, and electric power and propulsion systems for the U.S. military.
The defense sector has been one of the market's strongest performers in recent months, buoyed by rising global defense budgets, geopolitical tensions, and modernization programs across NATO allies. Leonardo DRS has been a direct beneficiary, with its advanced electronics platforms seeing growing demand from the Department of Defense and allied militaries.
Today's move may be connected to a new contract award, an earnings beat, or broader sector momentum following positive defense spending signals from Washington. The company's focus on next-generation electronic warfare, infrared sensors, and naval power systems positions it squarely in the growth sweet spot of defense modernization.
Volume analysis: At nearly 3 million shares, volume was elevated and suggests meaningful institutional interest rather than retail-driven speculation.
Short-term outlook: Defense stocks tend to move on longer-term secular trends rather than single-day catalysts. If today's move was earnings-driven, traders should watch for analyst upgrades in the coming days. The defense spending backdrop remains structurally bullish, which could provide sustained support for DRS at these levels.
📈 BEAM (Beam Therapeutics) — +14.0% to $32.29 | Gene Editing Momentum
Beam Therapeutics, a pioneer in base editing — a next-generation evolution of CRISPR gene editing technology — jumped 14.0% to close at $32.29 on strong volume of 3.7 million shares. Beam's proprietary technology enables precise, single-letter changes to DNA and RNA without making double-stranded breaks, potentially offering a safer and more precise approach to gene editing than traditional CRISPR.
The gene editing sector has seen renewed investor enthusiasm in 2026, building on the landmark approval of CRISPR-based therapies in prior years. Beam has been advancing its pipeline across sickle cell disease, oncology, and other genetic conditions, and any positive readout from clinical trials or regulatory interactions could have triggered today's rally.
The broader gene therapy and editing space has also benefited from increased M&A activity, with large pharma companies looking to acquire next-generation editing platforms. Beam's unique base-editing technology makes it a potential acquisition target, which may be adding a speculative premium to the stock.
Volume analysis: Volume of 3.7 million shares was well above average, suggesting that today's move was driven by a specific catalyst rather than general sector rotation.
Short-term outlook: Beam's trajectory is heavily dependent on clinical data readouts. Investors should monitor the company's upcoming catalysts calendar closely. As with all clinical-stage biotechs, position sizing and risk management are critical — the same data-driven volatility that produces 14% up days can work in the opposite direction.
Notable Themes: Crypto Miners Rally in Tandem
📈 CIFR (+12.5%) & WULF (+12.0%) — Bitcoin Mining Stocks Surge
Two of today's top gainers — Cipher Mining (CIFR) and TeraWulf (WULF) — are Bitcoin mining companies that rallied in lockstep, both gaining over 12% on enormous volume. CIFR traded 51.2 million shares while WULF saw 46.1 million shares change hands, making them among the most actively traded stocks of the session.
The synchronized move in crypto mining stocks strongly suggests that Bitcoin itself had a significant positive move today, which tends to amplify through mining stocks due to their operational leverage to the price of BTC. Mining companies are essentially leveraged bets on Bitcoin — when BTC rises, their profit margins expand dramatically since their costs (energy, hardware) are relatively fixed while revenue scales with Bitcoin's price.
Both CIFR and WULF have also been positioning themselves as AI/high-performance computing (HPC) plays, leveraging their existing power infrastructure and data center assets to pivot toward AI workloads. This dual narrative — crypto mining plus AI infrastructure — has made these stocks particularly attractive to momentum investors in the current market environment.
Caution: Crypto mining stocks are among the most volatile names in the market. They can deliver spectacular gains on Bitcoin rallies, but they can also give back those gains just as quickly during pullbacks. Traders should be aware of the correlation to Bitcoin's price action and the inherent volatility of the space.
Other Notable Movers
ZETA (Zeta Global) — +13.3% to $16.98
Zeta Global, the AI-powered marketing technology platform, surged 13.3% on heavy volume of 18.3 million shares. Zeta has been at the intersection of two powerful market themes: artificial intelligence and digital marketing optimization. The company's data cloud platform helps enterprises acquire, grow, and retain customers using AI-driven insights. A strong earnings report, renewed AI enthusiasm, or a strategic partnership could have been the catalyst. The elevated volume suggests institutional conviction behind the move.
WLK (Westlake Corporation) — +12.0% to $104.17
Westlake Corporation, a diversified chemicals and building products company, gained 12.0% on moderate volume of 1.8 million shares. Westlake manufactures performance and essential materials including PVC, polyethylene, and other specialty chemicals. The move could reflect strong quarterly earnings driven by improving housing starts, infrastructure spending, or favorable pricing dynamics in the chemicals sector. Cyclical names like WLK tend to rally when investors see signs of economic strength.
FRMI (Fermi Inc.) — +11.9% to $10.05
Fermi Inc. rounded out the top 10 with an 11.9% gain to $10.05 on volume of nearly 12.9 million shares. The relatively high volume for this name suggests that a meaningful catalyst drove the day's action. With the stock sitting right at the psychologically significant $10 level, traders should watch whether this serves as a launchpad for further gains or a consolidation zone.
Market Context: What's Driving Today's Broad-Based Rally?
The diversity of today's top gainers tells an interesting story about current market sentiment. We're not seeing a narrow, single-sector rally — instead, the gains are spread across technology (KEYS, UCTT), biotech (IBRX, BEAM), defense (DRS), crypto (CIFR, WULF), martech (ZETA), chemicals (WLK), and more. This kind of broad participation is generally a healthy signal for the overall market.
Several macro themes are converging to support risk appetite:
- AI Infrastructure Spending: The relentless demand for AI compute power continues to ripple through the entire technology supply chain. Companies like Keysight and Ultra Clean that enable the testing and manufacturing of advanced semiconductors are direct beneficiaries.
- Earnings Season Momentum: We're in the heart of Q4 2025 / Q1 2026 earnings season, and companies that deliver upside surprises are being aggressively rewarded. The market's willingness to push stocks up 15–23% on strong results suggests that investors are not yet positioned for the level of growth some companies are delivering.
- Crypto Resurgence: Bitcoin's strength is pulling the entire crypto mining ecosystem higher, with CIFR and WULF both posting double-digit gains on massive volume. The ongoing institutional adoption of digital assets and the evolving regulatory framework continue to support the space.
- Defense Spending Tailwinds: Geopolitical uncertainty and NATO modernization programs continue to underpin defense stocks, with Leonardo DRS being the latest beneficiary.
- Biotech Pipeline Progress: The gene editing and immunotherapy sectors continue to advance, with BEAM and IBRX both posting significant gains as their respective pipelines mature.
Overall, today's market action paints a picture of a market that still has appetite for growth and is willing to pay up for companies executing well. The combination of high volume across multiple names and double-digit percentage gains suggests that institutional capital is actively rotating into stocks with strong fundamental catalysts.
Key Takeaways for Investors
- KEYS led all gainers with a massive +23.1% move, likely earnings-driven, highlighting the strength in AI-adjacent test & measurement.
- IBRX saw the heaviest volume of the day (82M+ shares), signaling a major catalyst in the immunotherapy space.
- Semiconductor supply chain names like UCTT continue to benefit from the AI capex super-cycle.
- Crypto miners CIFR and WULF rallied in tandem on enormous volume, tracking Bitcoin's upward momentum.
- Broad sector participation across tech, biotech, defense, crypto, and chemicals suggests healthy overall market sentiment.
- Volume profiles across most names indicate institutional-quality moves rather than retail-driven speculation.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice. Always do your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.
댓글
댓글 쓰기